Trials / Unknown
UnknownNCT04576858
Clinical Utility of Circulating Tumor DNA in Gastro-Esophageal Cancer
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,950 (estimated)
- Sponsor
- Rigshospitalet, Denmark · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This is a prospective cohort study designed to evaluate the treatment effect as well as predictive and prognostic factors with special emphasis on the clinical utility of ctDNA in plasma in patients with gastroesophageal cancer. Patients with gastroesophageal cancer are included in 5 separate cohorts scheduled for * Surgical resection + perioperative chemotherapy (cohort 1) * Neoadjuvant chemoradiotherapy followed by surgical resection (cohort 2) * Definitive chemoradiotherapy with curative intent (cohort 3) * Systemic therapy with the intent to prolong survival (cohort 4) * Palliative treatment without the use of chemotherapy (cohort 5)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Circulating tumor DNA | Measurement of circulating tumor DNA from plasma over a period of 2 years. |
Timeline
- Start date
- 2020-02-03
- Primary completion
- 2025-02-01
- Completion
- 2025-07-01
- First posted
- 2020-10-06
- Last updated
- 2020-10-06
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT04576858. Inclusion in this directory is not an endorsement.